| Literature DB >> 6299712 |
R A Roth, B Maddux, K Y Wong, D M Styne, G Van Vliet, R E Humbel, I D Goldfine.
Abstract
A monoclonal antibody to the human insulin receptor was tested for its ability to inhibit the binding of 125I-insulin-like growth factor I (IGF-I) and 125I-insulin-like growth factor II (IGF-II) to their receptors in human placenta membranes and cultured human IM-9 lymphocytes. In both placenta membranes and IM-9 cells, the antibody progressively inhibited the binding of 125I-IGF-I to its receptor with a potency that was 300-fold less than its ability to inhibit the binding of 125I-insulin to its own receptor. In contrast, in human placenta membranes, this antibody inhibited the binding of 125I-IGF-II to its receptor only slightly. These studies indicate, therefore, that this monoclonal antibody binds preferentially to the insulin receptor but also crossreacts to a lesser extent with the IGF-I receptor.Entities:
Mesh:
Substances:
Year: 1983 PMID: 6299712 DOI: 10.1210/endo-112-5-1865
Source DB: PubMed Journal: Endocrinology ISSN: 0013-7227 Impact factor: 4.736